Vocxi Health

Vocxi has created a breathalyzer for cancer and other serious ailments. With 1 minute of breathing on a mobile device, an immediate result is available. The mission is to make early detection, simple.

1. MD Anderson Cancer Center is our clinical partner. We have a lung cancer study/trial underway
2. In early production: Hardware, software/data infrastructure, mobile app complete
3. Successful feasibility studies in lung cancer, heart disease, covid, and poisons. Statistically significant P-values in every study.
4. Multiple recognitions: Blue Knight Company - a partner with the US government agency BARDA, focused on national security and preparedness against chemical, biological, & nuclear threats
5. Selected as 1 of 5 startups in the world to present at SXSW 2025
6. 40 granted patents

50% of cancers and diseases are discovered late when options are limited. We make early detection simple to improve patient outcomes.

We have a handheld mobile breathalyzer called MyBreathPrint. It’s a platform that can be used for any cancer or serious ailment like Alzheimer’s or sepsis. With 1 minute of breathing we capture a health snapshot by measuring thousands of biomarker patterns. Our technology combines quantum sensors, novels chemistry and ML and is protected by 40 granted patents.

1. Contract agreement with payer/providers “Payviders” (B2B)
2. Drive early revenue with our veterinary business. (Ethos Vet Health, the largest emergency health system in the world is our veterinary partner.)
3. Over time, our technology will sell into larger channels with telehealth/health at home companies. (Pre-emptive diagnostics)
4. Contracts with US Government

GSD Network. Gary Fowler.
Boston Scientific - Internal Development